The Daily Brief

October 30, 2026

Federal courts are shaping cannabis policy faster than Congress can legislate it. On October 29, a New York appeals court unanimously upheld the state's $200 million public financing program for marijuana dispensaries, rejecting arguments that state funding for federally prohibited cannabis violates the Controlled Substances Act. The judges found no conflict between state and federal law—providing financial assistance to state-licensed businesses doesn't require anyone to break federal law, and it doesn't shield operators from federal enforcement. Context This ruling signals that states moving ahead with legalization won't face legal blockades from their own court systems, even when federal scheduling remains technically in place.

Meanwhile, the DEA is fighting hard to contain damage from a damaging federal watchdog report. In briefs filed Thursday, the agency urged an administrative law judge to give "no weight" to a Government Accountability Office report documenting that the DEA and FDA lack written policies governing drug scheduling procedures. The GAO found gaps in how agencies evaluate controlled substances, make scheduling recommendations, and assess abuse potential. Opponents of marijuana rescheduling—including the National Drug & Alcohol Screening Association and DUID Victim Voices—filed separate briefs arguing the GAO report deserves decisive weight precisely because it exposes the absence of formal standards guiding the government's cannabis review. Money The outcome of this procedural fight could determine whether Trump's rescheduling proposal survives judicial scrutiny.

Congressional momentum is accelerating independent of the executive branch. Representative Steve Cohen (D-TN) introduced the Public Health and Research Reforms in Controlled Substances Act, which would completely deschedule marijuana rather than move it to a lower schedule, while overhauling 50+ years of federal drug policy. Representative Dina Titus (D-NV), co-chair of the Congressional Cannabis Caucus, backed the bill Thursday, calling it time to "modernize our laws to reflect the reality of cannabis use in the United States." The legislation would also eliminate mandatory minimum drug sentences and transfer some DEA regulatory authority to the Department of Health and Human Services. Notable Cohen called it the most comprehensive overhaul of the Controlled Substances Act since its enactment in 1970.

In state-level politics, federal rescheduling is shifting local conversations. Kansas Democratic gubernatorial candidate Cindy Holscher said Trump's rescheduling move is making Republican legislators more open to medical marijuana legalization, even as her GOP opponent, Senate President Ty Masterson, continues blocking bills in his chamber. New polling from Fort Hays State University shows 65 percent of Kansans support medical marijuana legalization and 58 percent back recreational use—including majorities of Republicans. Holscher noted she previously got a medical marijuana bill passed in the Kansas House but it died in Masterson's Senate.

Employment law is catching up to state legalization in uneven ways. A 12-year New York State Police veteran filed suit Thursday seeking reinstatement after his 2025 termination for testing positive for THC during off-duty random drug screenings. Alexsandr DelCorvo, supported by the State Police union, argued his occasional use of CBD gummies for pain management was protected under New York's 2021 legalization law. A disciplinary hearing panel unanimously recommended he keep his job with suspension and probation, but the State Police superintendent rejected that recommendation. The lawsuit challenges whether state police have authority to fire officers for legal off-duty cannabis consumption when no impairment occurred on duty.

Finally, courts are beginning to hear challenges to state-level cannabis restrictions. A November 2 hearing is scheduled in Texas over a lawsuit challenging the state health department's attempt to classify hemp cannabinoid products as controlled substances, while Idaho voters will decide on a constitutional amendment that would strip voters of the power to create cannabis initiatives, leaving all decisions to the legislature. Context Between federal rescheduling, state court rulings protecting legalization programs, congressional bills, and employment lawsuits, cannabis regulation is fragmenting across multiple levels of government—each moving at different speeds.

October 30, 2026

Alabama's medical marijuana program is expanding rapidly, with two additional dispensaries set to open next week and over 2,300 patient identification cards now issued statewide. Callie's Apothecary is preparing to open its third location in Bessemer, while Bama Bloom launches a new dispensary in Birmingham, bringing Alabama's total to five operating retail sites. Money The state's three existing dispensaries are projected to generate $130,000 to $140,000 in October sales, with monthly revenue exceeding $120,000 over the previous two months. Alabama currently has 83 physicians certified to recommend medical marijuana and five active cultivators supporting the growing patient base, though litigation over integrated facility licensing continues to prevent full deployment of the state's potential 37 total dispensaries.

In a significant development for federally regulated cannabis research, AJNA Biosciences, a Colorado-based biotechnology company, has applied for DEA authorization to manufacture whole-plant marijuana, marijuana extracts, and THC as part of a new FDA-regulated drug program. Notable The application, filed September 30 and disclosed October 30, marks a formal pathway toward clinical trials and pharmaceutical development of cannabis-derived medicines under federal supervision. The company previously received DEA approval to manufacture psilocybin for research purposes and now seeks to expand its federally regulated manufacturing into cannabis derivatives. The DEA notice provides a 60-day public comment period, with any resulting pharmaceutical products remaining subject to FDA requirements—establishing a clear distinction between federally supervised clinical research and state-licensed retail cannabis.

Money Multistate operators continue consolidating market share across mature states. Verano has opened a new Zen Leaf dispensary in Ephrata, Pennsylvania, a prime Lancaster County location, while Norman Yousif's Off The Charts launched a new Santa Monica dispensary on Wilshire Boulevard. In Ohio, cannabis sales jumped 25% since the state banned hemp-derived THC products sold outside licensed marijuana retailers, demonstrating how regulatory consolidation benefits established MSOs. Vireo, a multistate operator with operations across multiple markets, is pursuing acquisitions and organic growth to push revenue past $100 million per market, while Pennsylvania's medical marijuana sector has become dominated by multistate cannabis corporations.

Context The cannabis business landscape reflects two parallel regulatory tracks: state-licensed retail markets operating under prohibition of various intoxicating hemp alternatives, and federal Schedule I research pathways now formally integrating cannabis into FDA-regulated drug development. These concurrent systems—one restricting competition to licensed operators, the other enabling pharmaceutical development—suggest the industry's evolution toward both commercial standardization and scientific legitimacy over the next few years.

October 30, 2026

Federal restrictions on synthetic hemp cannabinoids take effect November 12, triggering an industry-wide scramble as businesses face the most significant regulatory crackdown on intoxicating hemp products since the 2018 Farm Bill created the loophole. Money Upstate Elevator's "Death of Hemp Sale" is already underway, with THC drinks nearly depleted as retailers nationwide rush to clear inventory before the deadline. Hemp drink founders are shifting strategy entirely—some pivoting away from beverage formats altogether—while industry voices warn Congress that without legislative action, thousands of small hemp businesses face closure within weeks.

The ban targets synthetic cannabinoids derived from hemp, a category that includes many popular THC beverages currently legal in states like Illinois, Ohio, and elsewhere. Retailers in Illinois still face the November 12 deadline to pull hemp-derived THC beverages from shelves, and similar clearance deadlines are sweeping across compliant states. Notable Meanwhile, companies like Wims are adapting by introducing new micro-dose formulations—their expanded Pocket-Tonic line now features a 2mg dose designed for controlled, sessionable experiences—suggesting that innovation will continue even as the regulatory landscape tightens.

The broader economic question remains unresolved. Industrial hemp farmers face an uncertain future as federal policy oscillates, and smaller producers lack the capital to pivot quickly. Guest columns published today in outlets like NOLA.com are calling on Congress to intervene before the industry collapses, arguing that a blanket ban destroys legitimate agricultural and manufacturing jobs without replacing them with clear regulatory alternatives.

On the employment front, cannabis employers are taking healthcare benefits into their own hands by exploring healthcare captives—self-insured employee benefit structures—to manage costs and provide competitive coverage in an industry still largely excluded from federal insurance programs. Context The cannabis workforce now spans cultivation, retail, manufacturing, beverages, and ancillary services, yet basic employee protections like health insurance remain fragmented and locally dependent rather than federally standardized.

Internationally, the EU is moving toward recognizing the whole hemp plant as an agricultural crop, though individual states will retain power to criminalize cultivation and use—a model that contrasts sharply with the binary federal approach in the United States. As the November 12 deadline approaches, the U.S. hemp beverage industry is essentially in clearance mode, waiting for Congressional action that may not arrive in time.

October 30, 2026

Researchers have achieved a significant breakthrough in topical CBD delivery, developing a new formulation that penetrates human skin seven times more effectively than conventional oil-based products while substantially reducing inflammatory markers. Scientists at Spain's CIDETEC and Biogipuzkoa Health Research Institute created a polypeptide-stabilized oil-in-water emulsion that encapsulates CBD in microscopic droplets capable of reaching deeper epidermal layers. In reconstructed human skin exposed to ultraviolet B radiation, the encapsulated formulation reduced inflammatory proteins IL-6 and IL-8 by 93% and 73%, respectively, compared with untreated irradiated cells—dramatically outperforming conventional CBD. Notable The formulation maintained stability over 18 months of storage with 99% encapsulation efficiency and showed no evidence of skin irritation.

In separate molecular research published in the Journal of Molecular Pathology, scientists from the University of Antioquia and Texas Tech University Health Sciences Center identified 22 genes whose expression was altered by CBD across five different human cell types, with hundreds more showing changes in subsets of those cells. The research focused on genes involved in endoplasmic reticulum stress, lipid metabolism, and cholesterol regulation—revealing that CBD influences five important transcription factors: ATF4, ATF6, XBP1, SREBF1, and SREBF2. The findings suggest that CBD's molecular effects are highly dependent on cellular context, meaning the compound activates different biological programs depending on which type of human cell it encounters.

Context Meanwhile, the federal policy landscape around cannabis continues to shift. Rep. Steve Cohen (D-TN) introduced the Public Health and Research Reforms In Controlled Substances Act on Thursday, an 89-page bill that would completely overhaul the federal drug scheduling system by replacing the Nixon-era five-schedule framework with a dual-axis approach that separately evaluates abuse potential and therapeutic value. The bill would also federally legalize marijuana by removing it from the Controlled Substances Act entirely—a process called descheduling that would transfer scheduling authority from the Department of Justice and DEA to the Department of Health and Human Services. This development comes as the Trump administration pursues a more incremental rescheduling process that would move cannabis from Schedule I to Schedule III.